Inhaled tobramycin-associated hearing loss in an adolescent with renal failure.
Tobramycin for inhalation is a mainstay of therapy for cystic fibrosis. Routine monitoring of serum concentrations is not performed for patients receiving tobramycin by this route. This is a case of an adolescent with cystic fibrosis, renal failure and a serum concentration of 13.4 mg/dL who was diagnosed with profound sensorineural hearing loss after 3 weeks of inhaled tobramycin therapy.
Patatanian
Leslie
L
Department of Pharmacy, Integris Baptist Medical Center, Oklahoma City, OK, USA. Leslie.Patatanian@integris-health.com
D000280:Administration, Inhalation; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy*; D006319:Hearing Loss, Sensorineural / Q000209:etiology*; D006801:Humans; D008297:Male; D051437:Renal Insufficiency; D014031:Tobramycin / Q000008:administration & dosage / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; D014031:Tobramycin